EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib

Taeyun Kim, Junsu Choe, Sun Hye Shin, Byeong-Ho Jeong, Kyungjong Lee, Hojoong Kim, Se-Hoon Lee, Sang-Won Um iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0310079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Taeyun Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Pulmonary and Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, …. Hauptthemen laut MEDLINE: Acrylamides, ErbB Receptors, Aniline Compounds, Lung Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study was performed to investigate the detection rate of EGFR T790M mutation by repeated rebiopsy, to identify the clinical factors related to repeated rebiopsy, and to assess survival outcomes according to the methods and numbers of repeated rebiopsies in patients with lung adenocarcinoma who received sequential osimertinib after failure of previous 1st or 2nd generation EGFR-tyrosine kinase inhibitors.

Methods

This retrospective study included patients with advanced-stage lung adenocarcinoma who were confirmed to have EGFR T790M mutation and to have received osimertinib from January 2020 to February 2021 at Samsung Medical Center. The presence of T790M mutation was assessed based on either plasma circulating tumor DNA (ctDNA) or tissue specimens.

Results

A total of 443 patients underwent rebiopsy, with 186 (42.0%) testing positive for the T790M mutation by the sixth rebiopsy. The final analysis included 143 eligible patients. Progression-free survival was not significantly different in terms of the methods (tissue: 13.3 months, 95% confidence interval [CI]: [9.4, 23.5] vs plasma: 11.1 months, 95% CI: [8.1, 19.4], p = 0.33) and numbers (one: 13.4 months, 95% CI: [9.4, 23.5] vs two or more: 11.0 months, 95% CI: [8.1, 14.8], p = 0.51) of repeated rebiopsies. Longer overall survival (OS) was found in patients in whom T790M was detected by tissue specimens rather than by plasma ctDNA (2-year OS rate: 81.7% for tissue vs 63.9% for plasma, p = 0.0038). Factors related to the lower numbers of rebiopsies included age and bone metastasis. Factor associated with T790M detection in tissue rather than in plasma was pleural metastasis, while advanced tumor stage was related to T790M confirmation in plasma rather than in tissue.

Conclusions

Repeated rebiopsy for T790M detection in patients with NSCLC can increase the detection rate of the mutation. Detection of T790M by plasma ctDNA might be related to poor survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesErbB ReceptorsAniline CompoundsLung NeoplasmsAdenocarcinoma of LungMutationHumansMaleFemaleAgedMiddle AgedRetrospective StudiesCirculating Tumor DNABiopsyTreatment OutcomeProtein Kinase InhibitorsAged, 80 and overAntineoplastic AgentsNeoplasm StagingAdultProgression-Free SurvivalIndolesPyrimidines

Substanzen

osimertinibAcrylamidesErbB ReceptorsAniline CompoundsEGFR protein, humanCirculating Tumor DNAProtein Kinase InhibitorsAntineoplastic AgentsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Medicine, Division of Pulmonary and Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea.
  • Department of Medicine, Division of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.

ORCID-Profile: Sang-Won Um

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Kim, T., Choe, J., Shin, S. H., Jeong, B. H., Lee, K., Kim, H., Lee, S. H., & Um, S. W. (2024). Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib. PLOS ONE. https://doi.org/10.1371/journal.pone.0310079

Vancouver

Kim T, Choe J, Shin SH, Jeong BH, Lee K, Kim H, et al. Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib. PLOS ONE. 2024. doi:10.1371/journal.pone.0310079

BibTeX
@article{Kim2024,
  author = {Kim, Taeyun and Choe, Junsu and Shin, Sun Hye and Jeong, Byeong-Ho and Lee, Kyungjong and Kim, Hojoong and Lee, Se-Hoon and Um, Sang-Won},
  title = {Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0310079}
}
Kostenlos starten →